These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units. Roos JF; Bulitta J; Lipman J; Kirkpatrick CM J Antimicrob Chemother; 2006 Nov; 58(5):987-93. PubMed ID: 16943209 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of several dosing regimens of cefepime, with various simulations of renal function, against clinical isolates of Pseudomonas aeruginosa in a pharmacodynamic infection model. Cappelletty DM Antimicrob Agents Chemother; 1999 Jan; 43(1):129-33. PubMed ID: 9869577 [TBL] [Abstract][Full Text] [Related]
4. β-Lactam Dosage Regimens in Septic Patients with Augmented Renal Clearance. Jacobs A; Taccone FS; Roberts JA; Jacobs F; Cotton F; Wolff F; Creteur J; Vincent JL; Hites M Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29987138 [TBL] [Abstract][Full Text] [Related]
5. Prospective monitoring of cefepime in intensive care unit adult patients. Chapuis TM; Giannoni E; Majcherczyk PA; Chioléro R; Schaller MD; Berger MM; Bolay S; Décosterd LA; Bugnon D; Moreillon P Crit Care; 2010; 14(2):R51. PubMed ID: 20359352 [TBL] [Abstract][Full Text] [Related]
6. Adequacy of high-dose cefepime regimen in febrile neutropenic patients with hematological malignancies. Sime FB; Roberts MS; Tiong IS; Gardner JH; Lehman S; Peake SL; Hahn U; Warner MS; Roberts JA Antimicrob Agents Chemother; 2015 Sep; 59(9):5463-9. PubMed ID: 26124158 [TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia. Nicasio AM; Ariano RE; Zelenitsky SA; Kim A; Crandon JL; Kuti JL; Nicolau DP Antimicrob Agents Chemother; 2009 Apr; 53(4):1476-81. PubMed ID: 19188394 [TBL] [Abstract][Full Text] [Related]
8. Low cefpirome levels during twice daily dosing in critically ill septic patients: pharmacokinetic modelling calls for more frequent dosing. Lipman J; Wallis SC; Rickard CM; Fraenkel D Intensive Care Med; 2001 Feb; 27(2):363-70. PubMed ID: 11396280 [TBL] [Abstract][Full Text] [Related]
9. Cefepime and continuous renal replacement therapy (CRRT): in vitro permeability of two CRRT membranes and pharmacokinetics in four critically ill patients. Isla A; Gascón AR; Maynar J; Arzuaga A; Toral D; Pedraz JL Clin Ther; 2005 May; 27(5):599-608. PubMed ID: 15978309 [TBL] [Abstract][Full Text] [Related]
10. Cefepime in critically ill patients: continuous infusion vs. an intermittent dosing regimen. Georges B; Conil JM; Cougot P; Decun JF; Archambaud M; Seguin T; Chabanon G; Virenque C; Houin G; Saivin S Int J Clin Pharmacol Ther; 2005 Aug; 43(8):360-9. PubMed ID: 16119511 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and pharmacodynamics of cefepime in patients with various degrees of renal function. Tam VH; McKinnon PS; Akins RL; Drusano GL; Rybak MJ Antimicrob Agents Chemother; 2003 Jun; 47(6):1853-61. PubMed ID: 12760858 [TBL] [Abstract][Full Text] [Related]
12. When pharmacodynamics trump costs: an antimicrobial stewardship program's approach to selecting optimal antimicrobial agents. Goff DA; Nicolau DP Clin Ther; 2013 Jun; 35(6):766-71. PubMed ID: 23795574 [TBL] [Abstract][Full Text] [Related]
13. A novel intraperitoneal cefepime regime based on pharmacokinetic modeling to treat CAPD peritonitis. Yuen SK; Yuen YP; Fok SP; Yong SP; Tse MW; Chan AY Perit Dial Int; 2010; 30(6):660-1. PubMed ID: 21148061 [No Abstract] [Full Text] [Related]
14. The importance of pharmacokinetic consultation of cefepime treatment for Pseudomonas aeruginosa bacteremia: a case report of severe thermal burn injury. Aoki Y; Urakami T; Magarifuchi H; Nagasawa Z; Nagata M; Fukuoka M J Infect Chemother; 2011 Jun; 17(3):407-11. PubMed ID: 20922450 [TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics of cefepime in febrile neutropenia: implications for dose-dependent susceptibility and contemporary dosing regimens. Rhodes NJ; Grove ME; Kiel PJ; O'Donnell JN; Whited LK; Rose DT; Jones DR; Scheetz MH Int J Antimicrob Agents; 2017 Sep; 50(3):482-486. PubMed ID: 28668694 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and pharmacodynamics of cefepime administered by intermittent and continuous infusion. Burgess DS; Hastings RW; Hardin TC Clin Ther; 2000 Jan; 22(1):66-75. PubMed ID: 10688391 [TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics and dosing simulations of cefepime in septic shock patients receiving continuous renal replacement therapy. Carlier M; Taccone FS; Beumier M; Seyler L; Cotton F; Jacobs F; Roberts JA Int J Antimicrob Agents; 2015 Oct; 46(4):413-9. PubMed ID: 26208469 [TBL] [Abstract][Full Text] [Related]
18. Low cefepime concentrations during high blood and dialysate flow continuous venovenous hemodialysis. Wilson FP; Bachhuber MA; Caroff D; Adler R; Fish D; Berns J Antimicrob Agents Chemother; 2012 Apr; 56(4):2178-80. PubMed ID: 22290968 [TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of continuous infusion of piperacillin in critically ill patients. Dhaese SAM; Roberts JA; Carlier M; Verstraete AG; Stove V; De Waele JJ Int J Antimicrob Agents; 2018 Apr; 51(4):594-600. PubMed ID: 29277531 [TBL] [Abstract][Full Text] [Related]
20. Steady-state pharmacokinetics and pharmacodynamics of cefepime administered by prolonged infusion in hospitalised patients. Cheatham SC; Shea KM; Healy DP; Humphrey ML; Fleming MR; Wack MF; Smith DW; Sowinski KM; Kays MB Int J Antimicrob Agents; 2011 Jan; 37(1):46-50. PubMed ID: 21074370 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]